|
- Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit Hyperactivity Disorder (ADHD) and anxiety associated disorders
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention . . .
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications Cingulate is headquartered in Kansas City, Kansas
- Stock Quote Chart - Cingulate Inc
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment Cingulate Inc Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and . . .
“Cingulate has made meaningful progress this quarter toward key value-creating milestones,” said Jay Roberts, Executive Chairman of Cingulate
- SEC Filings - Cingulate Inc
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
- 0001493152-24-031469 | 10-Q | iXBRL Viewer | Cingulate INC
Cingulate Inc records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations
- Form 8-K for Cingulate INC filed 10 14 2025
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications Cingulate is headquartered in Kansas City, Kansas For more information, visit Cingulate com
- Press Releases - Cingulate Inc
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan , Aug 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed
|
|
|